Page 90 - 2020Taiwan Food and Drug Administration Annual Report
P. 90

Implementation Strategy
                  Implementation Strate    gy
                  I.  Actively participated in the events held by the European Network of
                     2I¿FLDO &RVPHWLFV &RQWURO /DERUDWRULHV  2&&/V
                                                           th
                       In 2019, we sent our delegates to join the 4  MRLQW PHHWLQJ RI (XURSHDQ 1HWZRUN RI 2I¿FLDO
                  Cosmetics Control Laboratories (OCCLs) and the Committee for Cosmetics and Consumer
                  Health (CD- P-COS) held in France. During the meeting, we reported TFDA’s newly developed

                  PHWKRG IRU WKH LGHQWL¿FDWLRQ RI DVEHVWRV ¿EHUV LQ FRVPHWLFV DQG H[FKDQJHG RSLQLRQV ZLWK H[SHUWV
                  from EU countries. We also actively participated in OCCLs’ activities such as peer reviews
                  of analytical methods for nitrosamines in cosmetics and post-market surveillance of allergens
                  in aroma products. Our aggressive participation in the international organizations establishes
                  communication channels and international networks, enhances our international visibility
                  and improves the capability of national laboratories to meet the requirements of international
                  standards.

                  ,,   6LJQHG WKH 0HPRUDQGXP RI 8QGHUVWDQGLQJ  0R8  ZLWK WKH (XURSHDQ
                     8QLRQ 2I¿FLDO &RQWURO $XWKRULW\ QHWZRUN  (8 2&$%5 QHWZRUN
                       In view of the fact that most of human vaccines used in Taiwan came from European

                  pharmaceutical companies and many fraud vaccine incidents happened around the world in the
                  past few years, TFDA and EU OCABR network signed the Memorandum of Understanding
                   0R8  FRQFHUQLQJ WKH SDUWLFLSDWLRQ LQ WKH DFWLYLW\ RI (XURSHDQ 8QLRQ 2I¿FLDO &RQWURO $XWKRULW\
                  Batch Release in 2019. TFDA collaborates with EU OCABR network to ensure the quality of
                  biologics through mutual information exchange. It would be helpful for us to timely keep up
                  ZLWK WKH XQTXDOL¿HG GUXJ QHZV KDSSHQHG LQ (XURSH  ZKLFK ZLOO KHOS 7DLZDQ WULJJHU D UHVSRQVH
                  mechanism to response to international incidents and safeguard the use of drugs for the citizens
                  in Taiwan.

                  ,,,  5HVXOWV RI SUR¿FLHQF\ WHVWV DQG FROODERUDWLYH VWXGLHV
                       The National Laboratory of TFDA has participated in 16 proficiency tests and 4
                  collaborative studies (Table 6-1) in 2019, which demonstrated its competence in analytic aspects

                  and earned full recognition from the world for its analytical ability.



















            88
   85   86   87   88   89   90   91   92   93   94   95